Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439270 | 0.99 | TP53 (0.46) | TP53LMNACHIARXFP1KDM4E | |
| SCHEMBL439517 | 0.88 | MTOR (0.43) | TP53LMNAL3MBTL1PIK3CDMAPT | |
| SCHEMBL441222 | 0.77 | KDM4E (0.42) | KDM4EL3MBTL1NPC1 | |
| SCHEMBL439522 | 0.72 | CNR1 (0.36) | KDM4E | |
| SCHEMBL440883 | 0.68 | CNR1 (0.40) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL440866 | 0.67 | GRM5 (0.46) | LMNAKDM4EHCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL12024793 | 0.66 | CHIA (0.47) | TP53LMNACHIAMAPT | |
| SCHEMBL23083866 | 0.64 | LMNA (0.44) | TP53LMNACHIARXFP1MAPT | |
| SCHEMBL9685127 | 0.64 | HDAC6 (0.43) | TP53LMNACHIAMAPTSMN1; SMN2 | |
| SCHEMBL15461690 | 0.64 | ALDH1A1 (0.45) | MEN1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | TP53 4871/4885LMNA 3745/4885CHIA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.